Cargando…

Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study

AIMS: The international IMPROVE™ observational study investigated the safety profile and effectiveness of biphasic insulin aspart 30/70 (BIAsp 30) in the routine treatment of patients with type 2 diabetes. We present analyses for the subgroup of patients who switched from basal insulin to BIAsp 30....

Descripción completa

Detalles Bibliográficos
Autores principales:	Gumprecht, J, Benroubi, M, Borzi, V, Kawamori, R, Shaban, J, Shah, S, Shestakova, M, Wenying, Y, Ligthelm, R, Valensi, P
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2009
Materias:	Late Breakers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2734926/ https://www.ncbi.nlm.nih.gov/pubmed/19504715 http://dx.doi.org/10.1111/j.1742-1241.2009.02064.x

Ejemplares similares

Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix® 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study
por: Shah, S, et al.
Publicado: (2009)

Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement
por: Unnikrishnan, A G, et al.
Publicado: (2009)

Patient treatment satisfaction after switching to NovoMix(®) 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors
por: Brod, Meryl, et al.
Publicado: (2010)

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
por: Valensi, Paul
Publicado: (2009)

Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: A consensus statement
por: Brito, Miguel, et al.
Publicado: (2011)

Ten Years of Experience with Biphasic Insulin Aspart 30: From Drug Development to the Latest Clinical Findings
por: Liebl, Andreas, et al.
Publicado: (2012)

A 32-Week Randomized Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp 30) Versus Basal–Bolus Therapy in Insulin-Naïve Patients with Type 2 Diabetes
por: Linjawi, Sultan, et al.
Publicado: (2017)

A commentary on the “consensus statement” regarding the use of BIAsp30
por: Kawamori, Ryuzo
Publicado: (2010)

Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results
por: Güler, Serdar, et al.
Publicado: (2009)

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
por: McCrimmon, Rory J., et al.
Publicado: (2022)

Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes: GEMELLI M Substudy
por: Mohan, Viswanathan, et al.
Publicado: (2022)

Composite cardiovascular risk and BMI affected comparative profiles of BIAsp 30 + metformin vs BIAsp 30 monotherapy: a MERIT post-hoc analysis
por: Guo, Lixin, et al.
Publicado: (2021)

Biphasic human insulin 30 thrice daily, is it reasonable?
por: Saadeh, Nesreen A., et al.
Publicado: (2020)

Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)
por: Aravind, S. R., et al.
Publicado: (2022)

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
por: Chacra, A R, et al.
Publicado: (2009)

Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving biphasic insulin aspart 30 or biphasic human insulin 30
por: Ohta, Akio, et al.
Publicado: (2011)

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
por: Heise, Tim, et al.
Publicado: (2009)

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes
por: Liebl, Andreas, et al.
Publicado: (2018)

An RCT Investigating Patient-Driven Versus Physician-Driven Titration of BIAsp 30 in Patients with Type 2 Diabetes Uncontrolled Using NPH Insulin
por: Chraibi, Abdelmjid, et al.
Publicado: (2017)

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
por: Shao, Hui, et al.
Publicado: (2022)

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK
por: McCrimmon, Rory J., et al.
Publicado: (2022)

Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen
por: Haddad, Jihad, et al.
Publicado: (2013)

Erratum to: An RCT Investigating Patient-Driven Versus Physician-Driven Titration of BIAsp 30 in Patients with Type 2 Diabetes Uncontrolled Using NPH Insulin
por: Chraibi, Abdelmjid, et al.
Publicado: (2017)

Clinical experience of switching from biphasic human insulin to biphasic insulin aspart 30 in Indian patients with type 2 diabetes in the A(1)chieve study
por: Das, A. K., et al.
Publicado: (2015)

Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring
por: Margaritidis, Charalampos, et al.
Publicado: (2021)

Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial
por: Polonsky, William H., et al.
Publicado: (2022)

Safety and Effectiveness of Biphasic Insulin Aspart 30 in Different Age-Groups: A(1)chieve Sub-Analysis
por: Khamseh, Mohammad Ebrahim, et al.
Publicado: (2013)

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
por: Niskanen, Leo, et al.
Publicado: (2012)

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
por: Onishi, Yukiko, et al.
Publicado: (2016)

Switching from basal or basal-bolus insulin to biphasic insulin aspart 30: Results from the Indian cohort of the A(1) chieve study
por: Bhattacharyya, Arpandev, et al.
Publicado: (2014)

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study
por: Farshchi, Amir, et al.
Publicado: (2016)

When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study
por: Jang, H C, et al.
Publicado: (2008)

OR30-04 Autonomous Drone Delivery of Insulin
por: O’Keeffe, Derek Timothy, et al.
Publicado: (2020)

Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics
por: Home, Philip D., et al.
Publicado: (2022)

Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial
por: Rosenstock, Julio, et al.
Publicado: (2021)

Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A(1)chieve® observational study
por: Yang, Wenying, et al.
Publicado: (2014)

The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review
por: Muszbek, N, et al.
Publicado: (2008)

Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy
por: Gorkin, L, et al.
Publicado: (2006)

T-01: Taux élevé d’infections respiratoires virales chez les patients hospitalisés et le personnel soignant, hiver 2014
por: Conort, G., et al.
Publicado: (2014)

Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial
por: Xu, Shaoyong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lh63vc963868rg029mddn9kkfu